附件二、投资者关系活动记录表 证券代码： 002275 证券简称：桂林三金 桂林三金药业股份有限公司投资者关系活动记录表 编号：2022009 | --- | --- | --- | --- | |----------------|---------------------------------|--------------------------------------------------|------------| | | | | | | 投资者关系活动 | ■ 特定对象调研 | □ 分析师会议 | | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | | □ 新闻发布会 | □ 路演活动 | | | | □ 现场参观 | □ 一对一沟通 | | | | □ 其他 | （请文字说明其他活动内容） | | | 参与单位名称及 | 华安证券 谭国超、李昌幸、江卉 | | | | 人员姓名 | | | | | 时间 | 2022 年 08 月 30 日 | | | | 地点 | 桂林三金药业股份有限公司会议室 | | | | 上市公司接待人 | 董事长：邹洵 | | | | 员 | 董事会秘书: ...

附件二、投资者关系活动记录表 证券代码： 002275 证券简称：桂林三金 桂林三金药业股份有限公司投资者关系活动记录表 编号：2022008 | --- | --- | --- | --- | --- | |-------------------|--------------------------------|--------------------------------------------------|------------------------------|-------| | | | | | | | 投资者关系活动 | ■ 特定对象调研 | □ 分析师会议 | | | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | | | □ 新闻发布会 | □ 路演活动 | | | | | □ 现场参观 | □ 一对一沟通 | | | | | □ 其他 | （请文字说明其他活动内容） | | | | 参与单位名称及 | 东方财富证券 何玮 | 侯伟青 | | | | 人员姓名 | 上海湘楚资产 熊龙启 | | | | | 时间 | 2022 年 08 月 26 日 | | | | | 地点 ...

桂林三金药业股份有限公司投资者关系活动记录表 编号：2022015 | --- | --- | --- | |-------------------------|-----------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | ■特定对象调研 | □ 分析师会议 | ...

桂林三金药业股份有限公司投资者关系活动记录表 编号：2022014 | --- | --- | |--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活动类别 | ■特定对象调研 □ 分析师会议 \n媒体采访 □业绩说明会 \n新闻发布会 □ 路演活动 现场参观 | | | □其他（请文字说明其他活动内容） | | 活动参与人员 | 国泰君安证券 蒋文杰、赖立格、李帅中 陆贤 广西银瓴资产管理有限公司 谭亚悦 广东嘉强私募管理有限公司 戴剑辉、何泳彬 上海牧鑫私募基金管理 ...

桂林三金药业股份有限公司投资者关系活动记录表 编号：2022013 | --- | --- | --- | |-------------------------|-----------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | ■特定对象调研 | □ 分析师会议 | | 投资者关系活动类别 | □ 媒体采访 □业绩说明会 | | | | □ 新闻发布会 □ 现场参观 | □ 路演活动 | | | □其他（请文字说明其他活动内容） | | | 活动参与人员 | 华安证券 ...

桂林三金药业股份有限公司投资者关系活动记录表 编号：2022012 | --- | --- | --- | |-------------------------|-----------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活动类别 | ■特定对象调研 \n□ 媒体采访 □业绩说明会 \n□ 新闻发布会 □ 现场参观 | □ 分析师会议 \n□ 路演活动 | | | □其他（请文字说明其他活动内容） | | | | 东方财富证券 何玮 东方财富 侯伟青 盘京资产 曹珊珊 | 唐佰强 | | 活动参与人员 | 长盛基金 周思聪 桂林三金董事长 邹洵 桂林三 ...

Revenue and Profit - Revenue for Q3 2022 reached ¥443,488,378.21, an increase of 18.03% year-over-year[7] - Net profit attributable to shareholders was ¥21,467,877.53, a decrease of 53.03% compared to the same period last year[7] - Net profit excluding non-recurring gains and losses was ¥14,655,019.81, up 97.43% year-over-year[7] - The company reported a basic earnings per share of ¥0.0281, a decrease of 64.61% compared to the same period last year[7] - The net profit attributable to shareholders of the listed company decreased by 53.03% to CNY 21,467,877.53 compared to the same period last year, primarily due to increased financial expenses and share-based payment provisions[16] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 97.43% to CNY 14,655,019.81, mainly due to the high non-recurring gains in the previous period from government subsidies[16] - The net profit for the current period is CNY 324,383,259.62, an increase from CNY 292,898,189.25 in the previous period, representing a growth of approximately 10.7%[33] - Operating profit for the current period is CNY 399,141,337.71, compared to CNY 361,237,488.69 in the previous period, indicating an increase of about 10.5%[33] - Total profit for the current period is CNY 395,977,951.32, up from CNY 361,468,249.37, reflecting a growth of approximately 9.5%[33] Assets and Liabilities - Total assets at the end of the period were ¥4,046,301,129.62, a decrease of 1.21% from the end of the previous year[7] - The total assets of the company were CNY 4,046,301,129.62, a decrease from CNY 4,095,868,127.50 at the beginning of the year[30] - The total liabilities amounted to CNY 1,115,823,550.33, down from CNY 1,256,050,962.24[30] - Shareholders' equity attributable to the parent company increased to ¥2,930,477,579.29, up 3.19% from the previous year[7] - The company's equity attributable to shareholders was CNY 2,930,477,579.29, an increase from CNY 2,839,817,165.26[30] Cash Flow - Cash flow from operating activities for the year-to-date was ¥245,023,811.12, down 15.94% year-over-year[7] - Cash received from operating activities decreased by 75.45% to CNY 44,575,648.45, mainly due to a reduction in government subsidies compared to the previous period[16] - Cash paid for purchasing goods and receiving services increased by 93.14% to CNY 418,554,988.76, driven by increased sales and production[16] - Cash received from investment activities increased by 143.56% to CNY 473,707,824.13, mainly due to a higher number of maturing equity instruments[16] - Cash paid for investment activities surged by 1,699.65% to CNY 802,864,785.84, primarily due to increased investments in equity instruments[16] - Net cash flow from operating activities was $245,023,811.12, a decrease of 15.98% compared to $291,495,282.61 in the previous period[41] - Total cash inflow from investment activities was $555,924,903.30, down from $628,619,639.60, reflecting a decrease of 11.56%[41] - Cash outflow from investment activities increased significantly to $974,123,558.30 from $254,862,021.01, indicating a rise of 282.73%[41] - Net cash flow from financing activities was -$175,223,838.83, an improvement from -$295,805,366.73 in the previous period[41] - Cash inflow from financing activities totaled $266,396,014.38, compared to $209,692,691.28 in the previous period, marking an increase of 27.00%[41] - Cash outflow for dividend distribution and interest payments was $333,588,479.24, up from $244,001,210.05, representing a rise of 36.67%[41] Expenses - Management expenses rose by 55.64% to CNY 169,949,093.70, primarily due to the timely recognition of share-based payments[16] - Financial expenses decreased by 63.89% to CNY -5,784,980.30, attributed to increased loan interest and changes in the company's financial structure[16] - Research and development expenses decreased to CNY 127,378,100.62 from CNY 169,712,734.98, a reduction of about 25%[33] - Sales expenses increased to CNY 350,494,315.37 from CNY 309,789,625.49, marking an increase of approximately 13.1%[33] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 16,010[19] - The largest shareholder, Guilin Sanjin Group Co., Ltd., holds 62.05% of the shares, totaling 364,586,500 shares[19] Other Information - The company received FDA approval for clinical trials of its subsidiary's drug, indicating potential future growth in the pharmaceutical sector[23] - The company plans to change the purpose of its remaining repurchased shares, totaling 2,631,400 shares, to be used for cancellation to reduce registered capital[24] - The company did not undergo an audit for the third quarter report[44] - Other comprehensive income after tax for the current period is CNY 13,020,354.41, compared to a loss of CNY 1,854,021.31 in the previous period[37] - Basic and diluted earnings per share for the current period are both CNY 0.5547, an increase from CNY 0.5091 in the previous period[37] - The tax expenses for the current period amounted to CNY 71,594,691.70, compared to CNY 68,570,060.12 in the previous period, reflecting an increase of approximately 3%[33]

Financial Performance - The company's operating revenue for the first half of 2022 was approximately ¥995.47 million, representing a 13.13% increase compared to ¥879.90 million in the same period last year[28]. - Net profit attributable to shareholders was approximately ¥302.92 million, an increase of 22.54% from ¥247.19 million in the previous year[28]. - The net profit after deducting non-recurring gains and losses was approximately ¥290.27 million, reflecting a 35.19% increase from ¥214.72 million year-on-year[28]. - The basic earnings per share increased to ¥0.53, up 23.26% from ¥0.43 in the same period last year[28]. - The weighted average return on equity rose to 10.28%, an increase of 2.26% compared to 8.02% in the previous year[28]. - Total assets at the end of the reporting period were approximately ¥4.08 billion, a slight decrease of 0.37% from ¥4.10 billion at the end of the previous year[28]. - Net assets attributable to shareholders increased to approximately ¥2.88 billion, up 1.53% from ¥2.84 billion at the end of the previous year[28]. - The company reported a net cash flow from operating activities of approximately ¥209.39 million, a 4.66% increase from ¥200.07 million in the previous year[28]. - The company plans not to distribute cash dividends or issue bonus shares for this reporting period[6]. Market Environment and Industry Trends - The pharmaceutical manufacturing industry in China saw a revenue of CNY 1,400.78 billion, a year-on-year decrease of 0.60%, with profit totaling CNY 220.95 billion, down 27.60% year-on-year[37]. - The pharmaceutical industry is undergoing a period of adjustment and fluctuation, influenced by policies promoting innovation and strict regulation[37]. - The overall market environment for the pharmaceutical industry is characterized by dual pressures from administrative regulation and market competition[37]. - The company faces risks such as fluctuations in raw material prices and intensified market competition, which investors should be aware of[6]. - The company is facing risks from industry policy changes, particularly related to drug price reductions due to national procurement policies, with an average price drop of 21.8% in certain regions[153]. - The OTC market is expected to face increased competition as prescription drugs transition to non-prescription status, impacting companies focused on OTC products[153]. Product Portfolio and Development - The company holds 218 drug approvals, including 46 unique specialty varieties, with 70 specifications included in the National Essential Medicines List and 113 specifications in the National Medical Insurance Directory[43]. - The company has 64 valid invention patents, including one US invention patent and four patents awarded for excellence in China[43]. - The company aims to strengthen its leadership in the fields of oral and urinary system medications, continuing to grow steadily[40]. - The company has launched a new dosage form of Sanjin Pian, Sanjin Granules, which officially went on sale in 2021[51]. - The company is focused on expanding its product line and enhancing its market presence through innovative product development and strategic partnerships[46]. - The company is committed to ongoing research and development to improve existing products and introduce new therapies to meet market demands[46]. - The company has launched new products, including the Xiguashuang throat lozenge, which has received multiple awards and recognitions, including a national invention patent[55]. - The company is focusing on new product development, particularly in the health food sector, with specific products like Sanjin brand ginseng tablets and other herbal products[147]. Marketing and Sales Strategy - The company has a comprehensive marketing system established across the country, ensuring reliable drug quality and competitive advantages[40]. - The company aims to leverage its strong product portfolio to capture a larger share of the healthcare market, particularly in traditional Chinese medicine[46]. - The company plans to expand its market presence by entering new regions, targeting a 20% increase in market share by the end of 2023[67]. - The company plans to enhance hospital channel development and clinical promotion for its new product "Shu Yan Qing," which has significant market potential[134]. - The company will implement a "one province, one product, one strategy" promotion pilot for second-line exclusive products and continue to replicate and promote third-line exclusive and generic products in other markets[154]. - The company plans to accelerate the nationwide promotion of its value marketing model and optimize channel management to enhance terminal output[154]. Research and Development - The company has invested in R&D projects, including the deep secondary development of SanJin tablets and the development of new biopharmaceuticals[93]. - The company is focusing on research and development of new formulations, with a goal to introduce at least three new products by the end of 2023[67]. - The company is committed to improving cost efficiency across R&D, raw materials, production, and marketing to maintain profitability amid rising competition[153]. Corporate Social Responsibility and Compliance - The company has maintained compliance with environmental standards, with all monitored pollutants meeting the required discharge limits[165]. - The company has established a wastewater treatment system with a daily processing capacity of 2,500 tons, achieving a COD concentration of less than 500 mg/L after treatment[170]. - The company has contributed over 4 million yuan to social responsibility initiatives, including pandemic support and rural revitalization efforts[187]. Operational Challenges and Risk Management - The company has faced operational risks due to the ongoing COVID-19 pandemic and plans to innovate marketing strategies and enhance R&D efforts to mitigate short-term impacts on sales and performance[154]. - The management team has extensive experience and will actively monitor potential risks to ensure the successful completion of the 2022 operational plan and objectives[154]. - The company has faced challenges in the cultivation of raw materials due to environmental factors, impacting the efficiency of the "Modern Chinese Medicine Raw Material GAP Base" project[134]. - The company has successfully modified construction plans to save costs and ensure project completion despite geological challenges[134].

Financial Performance - The company's operating revenue for Q1 2022 was ¥516,891,871.81, representing a 20.32% increase compared to ¥429,589,921.89 in the same period last year[4] - Net profit attributable to shareholders for Q1 2022 was ¥120,053,789.34, up 22.92% from ¥97,672,179.84 in the previous year[4] - Basic and diluted earnings per share increased by 23.53% to ¥0.21 from ¥0.17 in the same period last year[4] - The net profit for the current period is 120,053,789.34, an increase from 97,672,179.84 in the previous period, representing a growth of approximately 22.8%[34] - The total comprehensive income for the current period is 119,558,821.49, compared to 97,672,179.84 in the previous period, indicating an increase of about 22.4%[34] Cash Flow - The net cash flow from operating activities decreased by 3.54% to ¥167,767,980.96 from ¥173,928,071.94 year-on-year[4] - Cash inflow from operating activities totals 638,327,757.79, compared to 555,330,275.03 in the previous period, showing an increase of approximately 14.9%[35] - Cash outflow from operating activities is 470,559,776.83, up from 381,402,203.09 in the previous period, indicating an increase of about 23.4%[38] - Cash flow from investing activities shows a net outflow of -73,360,724.97, compared to a net inflow of 15,397,513.24 in the previous period[38] - Cash flow from financing activities results in a net inflow of 12,206,733.48, contrasting with a net outflow of -87,001,816.04 in the previous period[38] - The ending cash and cash equivalents balance is 1,582,700,263.09, an increase from 1,076,974,962.17 in the previous period[38] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,182,069,870.01, a 4.61% increase from ¥3,997,591,280.48 at the end of the previous year[4] - Total liabilities decreased to CNY 1,214,732,993.38 from CNY 1,256,050,882.92, a reduction of 3.3%[27] - The company's cash and cash equivalents were CNY 2,570,656,056.23, up from CNY 2,454,133,198.86, reflecting a growth of 4.7%[24] - Inventory levels increased to CNY 299,514,679.21 from CNY 284,155,000.17, an increase of 5.4%[24] - The company reported a decrease in accounts payable to CNY 156,373,010.80 from CNY 159,775,165.75, a decline of 2.5%[24] Shareholder Information - The company holds 364,679,300 shares of common stock, representing 61.79% of total shares outstanding, making it the largest shareholder[14] - The first phase employee stock ownership plan holds 12,295,951 shares, accounting for 2.08% of the total share capital[14] - The company’s actual controller changed to Mr. Zou Xun, who holds a total of 22.38% of the company's shares through direct and indirect ownership[17] - The company’s stock repurchase account holds 2,631,400 shares, representing 0.45% of total shares[14] - The company’s major shareholders include Mr. Zou Jieming with 9.05% and other individuals holding less than 2% each[14] Expenses - Total operating costs amounted to CNY 368,017,919.17, up from CNY 305,059,286.27, reflecting a year-over-year increase of 20.6%[28] - Research and development expenses were CNY 70,056,723.81, compared to CNY 62,817,958.41, indicating an increase of 11.8%[28] - Management expenses surged by 85.39% to ¥43,085,926.29 from ¥23,241,227.25, primarily due to timely recognition of share-based payments[11] Government Subsidies - The company received government subsidies amounting to ¥6,880,460.97, an increase of 58.54% compared to ¥4,339,924.03 in the previous year[11] Accounts Receivable and Prepayments - Accounts receivable increased by 57.86% to ¥75,014,430.90 from ¥47,520,406.16 year-on-year, mainly due to increased sales[7] - Prepayments rose by 81.96% to ¥45,387,082.33 from ¥24,943,705.01, attributed to increased advance payments to suppliers[7] Audit Status - The company has not undergone an audit for the first quarter report[41]

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the year 2021, representing a year-on-year increase of 15%[19] - The net profit attributable to shareholders was RMB 300 million, an increase of 20% compared to the previous year[19] - The company's operating revenue for 2021 was ¥1,741,224,552.65, representing an increase of 11.15% compared to ¥1,566,484,673.44 in 2020[27] - The net profit attributable to shareholders for 2021 was ¥343,718,942.74, a 24.08% increase from ¥277,020,898.87 in 2020[27] - The net profit after deducting non-recurring gains and losses was ¥260,467,690.06, showing a 3.26% increase from ¥252,240,992.83 in 2020[27] - The basic and diluted earnings per share for 2021 were both ¥0.60, up 25.00% from ¥0.48 in 2020[27] - The profit margin for the total profit in 2021 was 24.67%, up from the previous year's profit margin[68] - The company reported a total revenue of CNY 1.5 billion for the fiscal year 2021, representing a year-over-year increase of 12%[178] Market Expansion and Strategy - The company is focusing on expanding its market presence in Southeast Asia, targeting a 30% growth in that region over the next two years[19] - User data showed an increase in active customers by 25%, reaching 1.5 million by the end of 2021[19] - The company plans to enhance the development and maintenance of hospital channels and increase clinical development and academic promotion for its second-line products due to their significant market potential[126] - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[19] - The company is exploring potential acquisitions to enhance its market presence, with a focus on companies in the herbal medicine sector[178] Research and Development - The company has invested RMB 50 million in research and development for new technologies in traditional Chinese medicine[19] - The company is investing CNY 200 million in R&D for new technologies aimed at enhancing product efficacy and safety[178] - R&D investment accounted for 11.63% of operating revenue, up from 9.85% the previous year[93] - The company is currently conducting multiple clinical trials for new biopharmaceutical products aimed at treating advanced malignancies, which are expected to enrich its product pipeline[90] - Research and development investments increased, resulting in 6 new invention patents and 10 ongoing projects in the biopharmaceutical pipeline, with 8 clinical approvals obtained[145] Product Development and Innovation - New product development includes the launch of three innovative herbal medicines, expected to contribute an additional RMB 100 million in revenue in 2022[19] - The company has established a leading position in the field of traditional Chinese medicine for oral and throat medications and urological products, recognized as one of China's top 50 traditional Chinese medicine companies[43] - The company has a robust pipeline of traditional Chinese medicine products, leveraging historical formulations for modern applications[59] - The company has developed multiple products including the Xigua Frost lozenge, which has received various awards and recognitions, including the National Invention Patent and the Guangxi Science and Technology Progress Second Prize[56] Financial Management and Governance - The company received government subsidies totaling CNY 76.36 million in 2021, which supported its operations during the challenging market environment[68] - The total pre-tax remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 6.08 million[182] - The company has established a comprehensive performance evaluation system for senior management, ensuring that remuneration is determined based on performance indicators[180] - The company maintains a strong governance structure, ensuring compliance with relevant laws and regulations, with no significant discrepancies noted with the guidelines set by the China Securities Regulatory Commission[157] Challenges and Risks - The board highlighted risks including raw material price fluctuations and increased market competition, urging investors to remain cautious[7] - The company is facing intensified market competition due to ongoing healthcare reforms and will promote value marketing models to optimize channel management[151] - The company will actively respond to the risks posed by industry policy changes and will adjust its product structure and marketing strategies accordingly[151] Employee and Management Structure - The total number of employees at the end of the reporting period is 2,677, with 1,495 in the parent company and 1,182 in major subsidiaries[196] - The company has established a compensation policy that reflects efficiency and fairness, aiming to attract and retain talent[200] - The company has maintained its current board structure with no new appointments or dismissals aside from the chairman transition[171] Sustainability and Corporate Responsibility - The management team emphasized a commitment to sustainability, with plans to reduce carbon emissions by 15% by 2025[178] - The company is adapting to market changes driven by aging population and health consumption upgrades, aiming for sustainable development[142]